Rheumatoid arthritis (RA) is clearly an immunological disease.' A number of aberrations have been described in the cellular arm of the immune response, for example, abnormal expression of interleukin 2 (IL2) receptors by T cells,2 reduced production of IL2, and defective regulation of Epstein-Barr virus (EBV) response in vitro. 4 Humoral processes also appear to be involved, as suggested by the presence tN=non-steroidal anti-inflammatory drugs; D=D-penicillamine;
P=prednisone.
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There was, however, a trend for more k than x bearing cells to express CD5 in patients with RA. Few EBV transformed normal B cells expressed pc 0.05 CD5 molecules (Fig. 3) 
